… (OPV2-c1 and OPV2-c2) designed to have similar immunogenicity, improved genetic …
safety and immunogenicity of the two novel OPV candidates compared with a monovalent Sabin …

… and introduction of more genetically stable type 2 polioviruses (novel OPV2) to respond to …
two novel OPV2 candidates are safe, well tolerated, and have immunogenicity similar to Sabin …

… (1·6–6·9%), compared with a sample of reverted Sabin monovalent OPV2 (90%) in the same
test. … Intestinal immune responses to type 2 oral polio vaccine (OPV) challenge in infants …

… for safety and immunogenicity in infants and children. These 2 novel poliovirus vaccines
had … This study was a phase 2 study with low and high doses of 2 novel OPV2 candidates in …

… variants compared with monovalent oral poliovirus vaccine type 2 (mOPV2). Phase 1 and …
Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared …

… , WHO authorised the use of a novel oral poliovirus vaccine type 2 (nOPV2) for outbreak …
Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared …

… an excellent safety and immunogenicity profile of mIPV2HD compared with currently … oral
poliovirus vaccine, type 2. *All randomised participants were included in the analyses of safety …

… with group C (difference in rates –3·7; 95% CI –7·9 to 0·3), but not for group A compared …
use led to the development of two novel OPV type 2 vaccine candidates (nOPV2), which were …

… poliovirus type 2 vaccine and later study with both novel … Both novel nOPV2 candidates
had comparable safety, tolerability, and immunogenicity as licensed Sabin mOPV2 vaccine [13]. …

… Novel oral polio vaccine type 2 (nOPV2) has been used to interrupt circulating vaccine-derived
poliovirus type 2 … data on the safety and immunogenicity of nOPV2 over two rounds of a …